NCT06859775View on ClinicalTrials.gov

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

January 31, 2027

Conditions
Recurrent or Metastatic Cervical Cancer
Interventions
DRUG

SHR-A1811

SHR-A1811 injection.

DRUG

Adebelimab injection

Adebelimab injection.

DRUG

Bevacizumab injection

Bevacizumab injection.

DRUG

SHR-8068

SHR-8068 injection.

DRUG

Cisplatin injection

Cisplatin injection.

DRUG

Carboplatin injection

Carboplatin injection.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY